Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized doubl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2024.2432353 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544063469223936 |
|---|---|
| author | Simon Valayer Marie Alexandre Mélanie Prague Abdoul Habib Beavogui Seydou Doumbia Mark Kieh Brian Greenwood Bailah Leigh Marie Poupelin Christine Schwimmer Samba O. Sow Irina Maljkovic Berry Jens H. Kuhn Daniela Fusco Natasha Dubois Cauwelaert Deborah Watson-Jones Rodolphe Thiébaut Yves Lévy Yazdan Yazdanpanah Laura Richert Edouard Lhomme |
| author_facet | Simon Valayer Marie Alexandre Mélanie Prague Abdoul Habib Beavogui Seydou Doumbia Mark Kieh Brian Greenwood Bailah Leigh Marie Poupelin Christine Schwimmer Samba O. Sow Irina Maljkovic Berry Jens H. Kuhn Daniela Fusco Natasha Dubois Cauwelaert Deborah Watson-Jones Rodolphe Thiébaut Yves Lévy Yazdan Yazdanpanah Laura Richert Edouard Lhomme |
| author_sort | Simon Valayer |
| collection | DOAJ |
| description | rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to evaluate waning of anti-Ebola virus (EBOV) glycoprotein (GP1,2) antibody concentrations after rVSVΔG-ZEBOV-GP or Ad26.ZEBOV, MVA-BN-Filo vaccination with linear mixed-effect regression models. After a post-vaccination peak, each vaccination strategy was associated with a decrease of anti-EBOV GP1,2 antibody concentrations with distinct kinetics, highlighting a less-rapid decline in antibody levels after vaccination by rVSVΔG-ZEBOV-GP. One year after administration of the vaccine, antibody concentrations were higher in children compared to adults for both vaccines, although with different effect sizes: 1.74-fold higher concentrations (95% confidence interval [CI] [1.48; 2.02]) for children 12–17 years old to 3.10-fold higher concentrations (95% CI [2.58; 3.69]) for those 1–4 years old compared to adults for Ad26.ZEBOV, MVA-BN-Filo versus 1.36-fold (95% CI [1.12; 1.61]) to 1.41-fold (95% CI [1.21; 1.62]) higher than these values for adults, with relatively small changes from one age category of children to another, for rVSVΔG-ZEBOV-GP. Antibody concentrations also differed according to geographical location, pre-vaccination antibody concentration, and sex. In combination with knowledge on memory response, characterization of the major determinants of immune response durability of both vaccinations may guide future EVD control protocols.Trial registration: ClinicalTrials.gov identifier: NCT02876328. |
| format | Article |
| id | doaj-art-0c49f2fb9f8e48d4b0939a6c4f0d61bb |
| institution | Kabale University |
| issn | 2222-1751 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-0c49f2fb9f8e48d4b0939a6c4f0d61bb2025-01-12T19:39:58ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512025-12-0114110.1080/22221751.2024.2432353Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trialSimon Valayer0Marie Alexandre1Mélanie Prague2Abdoul Habib Beavogui3Seydou Doumbia4Mark Kieh5Brian Greenwood6Bailah Leigh7Marie Poupelin8Christine Schwimmer9Samba O. Sow10Irina Maljkovic Berry11Jens H. Kuhn12Daniela Fusco13Natasha Dubois Cauwelaert14Deborah Watson-Jones15Rodolphe Thiébaut16Yves Lévy17Yazdan Yazdanpanah18Laura Richert19Edouard Lhomme20Infection, Antimicrobials, Modelling, Evolution (IAME), Université Sorbonne Paris Nord, Université Sorbonne Paris Cité, and Institut national de la santé et de la recherche médicale (Inserm), Paris, FranceBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, FranceBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, FranceCentre National de Formation et de Recherche en Santé Rurale (CNFRSR) de Mafèrinyah, Ministère de la Santé et de l’Hygiène Publique, Mafèrinyah, GuineaUniversity Clinical Research Center, University of Sciences, Technique and Technology of Bamako, Bamako, MaliPartnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, LiberiaLondon School of Hygiene & Tropical Medicine (LSHTM), London, UKCollege of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra LeoneBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, FranceEUropean CLInical Trials Platform & Development (EUCLID), Université de Bordeaux, Centre Hospitalier Universitaire Bordeaux, and Inserm, ISPED, Bordeaux, FranceCentre pour le Développement des Vaccins, Ministère de la Santé et du Développement Social du Mali, Bamako, MaliIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Frederick, MD, USAIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Frederick, MD, USAFrench Agency for Research on AIDS and Viral Hepatitis (ANRS), Emerging Infectious Diseases, PariSanté Campus, Paris, FranceInserm, Paris Cedex 13, FranceLondon School of Hygiene & Tropical Medicine (LSHTM), London, UKBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, FranceVaccine Research Institute, Faculté de Médicine, Université Paris-Est Créteil, Créteil, FranceInfection, Antimicrobials, Modelling, Evolution (IAME), Université Sorbonne Paris Nord, Université Sorbonne Paris Cité, and Institut national de la santé et de la recherche médicale (Inserm), Paris, FranceBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, FranceBordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, FrancerVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized double-blind clinical trial (PREVAC) were used to evaluate waning of anti-Ebola virus (EBOV) glycoprotein (GP1,2) antibody concentrations after rVSVΔG-ZEBOV-GP or Ad26.ZEBOV, MVA-BN-Filo vaccination with linear mixed-effect regression models. After a post-vaccination peak, each vaccination strategy was associated with a decrease of anti-EBOV GP1,2 antibody concentrations with distinct kinetics, highlighting a less-rapid decline in antibody levels after vaccination by rVSVΔG-ZEBOV-GP. One year after administration of the vaccine, antibody concentrations were higher in children compared to adults for both vaccines, although with different effect sizes: 1.74-fold higher concentrations (95% confidence interval [CI] [1.48; 2.02]) for children 12–17 years old to 3.10-fold higher concentrations (95% CI [2.58; 3.69]) for those 1–4 years old compared to adults for Ad26.ZEBOV, MVA-BN-Filo versus 1.36-fold (95% CI [1.12; 1.61]) to 1.41-fold (95% CI [1.21; 1.62]) higher than these values for adults, with relatively small changes from one age category of children to another, for rVSVΔG-ZEBOV-GP. Antibody concentrations also differed according to geographical location, pre-vaccination antibody concentration, and sex. In combination with knowledge on memory response, characterization of the major determinants of immune response durability of both vaccinations may guide future EVD control protocols.Trial registration: ClinicalTrials.gov identifier: NCT02876328.https://www.tandfonline.com/doi/10.1080/22221751.2024.2432353Ebola virus diseasevaccineimmunogenicityantibodyWestern Africamodelling |
| spellingShingle | Simon Valayer Marie Alexandre Mélanie Prague Abdoul Habib Beavogui Seydou Doumbia Mark Kieh Brian Greenwood Bailah Leigh Marie Poupelin Christine Schwimmer Samba O. Sow Irina Maljkovic Berry Jens H. Kuhn Daniela Fusco Natasha Dubois Cauwelaert Deborah Watson-Jones Rodolphe Thiébaut Yves Lévy Yazdan Yazdanpanah Laura Richert Edouard Lhomme Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial Emerging Microbes and Infections Ebola virus disease vaccine immunogenicity antibody Western Africa modelling |
| title | Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial |
| title_full | Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial |
| title_fullStr | Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial |
| title_full_unstemmed | Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial |
| title_short | Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial |
| title_sort | evaluation of waning of igg antibody responses after rvsvδg zebov gp and ad26 zebov mva bn filo ebola virus disease vaccines a modelling study from the prevac randomized trial |
| topic | Ebola virus disease vaccine immunogenicity antibody Western Africa modelling |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2024.2432353 |
| work_keys_str_mv | AT simonvalayer evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT mariealexandre evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT melanieprague evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT abdoulhabibbeavogui evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT seydoudoumbia evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT markkieh evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT briangreenwood evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT bailahleigh evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT mariepoupelin evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT christineschwimmer evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT sambaosow evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT irinamaljkovicberry evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT jenshkuhn evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT danielafusco evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT natashaduboiscauwelaert evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT deborahwatsonjones evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT rodolphethiebaut evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT yveslevy evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT yazdanyazdanpanah evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT laurarichert evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial AT edouardlhomme evaluationofwaningofiggantibodyresponsesafterrvsvdgzebovgpandad26zebovmvabnfiloebolavirusdiseasevaccinesamodellingstudyfromtheprevacrandomizedtrial |